ScholarIQanswers from OpenAlex & ORCID
Takeharu Yamanaka
ResearcherPublications, citations & collaboration network
Takeharu Yamanaka is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Takeharu Yamanaka have?
ScholarIQindexed works
Takeharu Yamanaka has 589 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Takeharu Yamanaka have?
ScholarIQcitation count
Takeharu Yamanaka has 21,460 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Takeharu Yamanaka?
ScholarIQh-index
Takeharu Yamanaka has an h-index of 68 in OpenAlex.
What is the i10-index of Takeharu Yamanaka?
ScholarIQi10-index
Takeharu Yamanaka has an i10-index of 254 in OpenAlex.
What is the ORCID of Takeharu Yamanaka?
ScholarIQorcid
The ORCID for Takeharu Yamanaka is on the source record.
What is the OpenAlex record for Takeharu Yamanaka?
ScholarIQopenalex
The OpenAlex for Takeharu Yamanaka is on the source record.
What are the most-cited papers on Takeharu Yamanaka?
ScholarIQmost cited works
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
Yojiro Hashiguchi, Kei Muro, Yutaka Saitō, Yoshinori Ito, Yoichi Ajioka, Tetsuya Hamaguchi, Kiyoshi Hasegawa, Kinichi Hotta, Hideyuki Ishida, Megumi Ishiguro, Soichiro Ishihara, Yukihide Kanemitsu, Yusuke Kinugasa, Keiko Nemoto Murofushi, Takako Eguchi Nakajima, Shiro Oka, Toshiaki Tanaka, Hiroya Taniguchi, Akihito Tsuji, Keisuke Uehara, Hideki Ueno, Takeharu Yamanaka, Kentaro Yamazaki, Masahiro Yoshida, Takayuki Yoshino, Michio Itabashi, Kentaro Sakamaki, Keiji Sano, Yasuhiro Shimada, Shinji Tanaka, Hiroyuki Uetake, Shigeki Yamaguchi, Naohiko YAMAGUCHI, Hirotoshi Kobayashi, Keiji Matsuda, Kenjiro Kotake, Kenichi Sugihara, Japanese Society for Cancer of the Colon and Rectum
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
Anne Aupérin, C. Le Péchoux, Estelle Rolland, Walter J. Curran, Kiyoyuki Furuse, P. Fournel, J. Belderbos, Gerald H. Clamon, H Cüneyt Ulutin, Rebecca Paulus, Takeharu Yamanaka, Marie‐Cécile Bozonnat, A. L. J. Uitterhoeve, Xiaofei Wang, Lesley Stewart, R. Arriagada, Sarah Burdett, Jean‐Pierre Pignon
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto Sobrero, Anthony F. Shields, Takayuki Yoshino, James Paul, Julien Taı̈eb, John Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca, Jeffrey A. Meyerhardt, Déwi Vernerey, Takeharu Yamanaka, Ioannis Boukovinas, Jeffrey P. Meyers, Lindsay A. Renfro, Donna Niedzwiecki, Toshiaki Watanabe, Valter Torri, Mark Saunders, Daniel J. Sargent, Thierry André, Timothy Iveson
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Takashi Seto, Terufumi Kato, Makoto Nishio, Kōichi Goto, Shinji Atagi, Yukio Hosomi, Noboru Yamamoto, Noboru Yamamoto, Toyoaki Hida, Makoto Maemondo, Kazuhiko Nakagawa, Seisuke Nagase, Isamu Okamoto, Takeharu Yamanaka, Kosei Tajima, Ryosuke Harada, Masahiro Fukuoka, Nobuyuki Yamamoto, Nobuyuki Yamamoto
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
Toshiaki Takahashi, Takeharu Yamanaka, Takashi Seto, Hideyuki Harada, Hiroshi Nokihara, Hideo Saka, Makoto Nishio, Hiroyasu Kaneda, Koichi Takayama, Osamu Ishimoto, Koji Takeda, Hiroshige Yoshioka, Motoko Tachihara, Hiroshi Sakai, Kōichi Goto, Nobuyuki Yamamoto